A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Panitumumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CONCERT-2
- Sponsors Amgen
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 02 Oct 2012 Patient numbers updated to 151